Open main menu

Psychiatrienet β

Zuclopenthixol MA-Chlorpromazine

Zuclopenthixol
Medium long acting
Type Antipsychotic
Group Thioxanthenes
links
PubChem 5311507
PubMed Zuclopenthixol
Kompas (Dutch) Zuclopenthixol
Wikipedia Zuclopenthixol
Chlorpromazine
Type Antipsychotic
Group Phenothiazines
links
Medscape Chlorpromazine
PubChem 2726
PubMed Chlorpromazine
Kompas (Dutch) Chlorpromazine
Wikipedia Chlorpromazine

Switch medication from Zuclopenthixol_MA to Chlorpromazine.[1] [2]

Nietinrijdenbord.png Stop Zuclopenthixol_MA
  • Day 1: Last depot injection
Eenrichtingbord.png Start Chlorpromazine
  • Day 1-4: approx. 25% of target dose
  • Day 5-8: approx. 50% of target dose
  • Day 9-12: approx. 75% of target dose
  • Day 13: target dose
Infobord.png More information
  • During this switch you could monitor ECG, especially in patients prone to QT-conduction problems.
  • There is a possibility of QT interval prolongation.[3]
  • Zuclopenthixol_MA = Zuclopenthixol acetate [4]
    StopDepotZucloMAStartOral13Days.jpg
Nietinrijdenbord.png — Zuclopenthixol_MA
Eenrichtingbord.png — Chlorpromazine


  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
  3. Stöllberger C, Huber JO, Finsterer J, Antipsychotic drugs and QT prolongation. Int Clin Psychopharmacol. 2005 Sep;20(5):243-51.
  4. SPC Zuclopenthixol acetate
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.